Actinium Pharmaceuticals Inc (ATNM)

[stockguard]

12:05 ET - Investors flee Actinium Pharmaceuticals after an interim analysis of its Phase 3 study of Iomab-B for bone marrow transplant conditioning, but Maxim Group says they should be buying. Actinium terms the pre-planned analysis successful and says the study's independent data monitoring committee recommends that it continue to full enrollment. Analysts at Maxim think investors may have been expecting to see data on the primary endpoint of six-month durable complete remission or for the trial be stopped for efficacy. Maxim notes that endpoint data was only viewed by the monitoring committee, not Actinium, and that the panel's recommendation that the trial move forward to completion is overall positive, and "we would be buyers of ATNM shares on today's weakness." Actinium down 23.2% to $8.23. ([e-mail])